Workflow
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
EVOKEvoke Pharma(EVOK) GlobeNewswire News Room·2024-10-01 12:30

Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at 8.16/shareSOLANABEACH,Calif.,Oct.01,2024(GLOBENEWSWIRE)−−EvokePharma,Inc.(NASDAQ:EVOK),aspecialtypharmaceuticalcompanyfocusedondevelopingtreatmentsforgastrointestinal(GI)diseases,withaparticularemphasisonGIMOTI®(metoclopramide)nasalspray,announcedtodaythatitreceivedapproximately8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it received approximately 3.0 million in gross proceeds from the amendment and exercise of existing warrants. The approx ...